New PSP for Lorlatinib in 2nd line ALK translocated - Amivantamab + Lazertinib in first line mEGFR - Amivantamab + CT in second line EGFR post Osimertinib -

Update 5 October 2025

Nivolumab + CT x 3

Lung – NSCLC / Neoadjuvant

Québec / Canada

4 mos.

positive 11 April 2022

Clinical Trials

12 mos.

positive 18 August 2022

Health Canada

3 mos.

positive 30 August 2023

INESSS (QC)

positive 30 March 2023

pCODR (CA)

4 mos.

positive 25 May 2023

pCPA

positive 27 September 2023

RAMQ / LM

Comparison with other countries

United States

United States

5 mos.

accepted 4 March 2022

FDA approval

Canada

Canada

10 mos.

accepted 18 August 2022

Health Canada

Europe

Europe

accepted 29 June 2023

EMA approval

Treatment is available on the hospital List of Medications (Liste des établissements)

Since the therapy will be given concomittantly with Chemotherapy, it will be at the expense of the hospital.

The choice of chemotherapy backbone in Checkmate 816 was gemcitabine + cisplatin or paclitaxel + carboplatin for the Squamous histology.

There was no advantage for the use of Cisplatin over Carboplatin. Paclitaxel + Carboplatin seems like the most suitable (despite the alopecia and neutropenia ; primary prophylaxis with GCSF is mandatory), but I believe every clinician should go with the treatment they are most comfortable with.

Despite the advantage in all PD-L1 subgroups and the good results we had for some of our PD-L1 neg patients, the benefit is substantially correlated to the PD-L1 expression. Patients with high PD-L1 benefited the most from this strategy.

Create an account

"*" indicates required fields

First name*

Last name*

Email*

Only institutional emails will be accepted

Permit number*

Username*

Password*

Enter Password Confirm Password

Strength indicator

Les renseignements ci-dessus [ou « ci-dessous »], c’est-à-dire collectés via ce formulaire nous sont nécessaires à la création de votre compte et pour vous permettre d’accéder à notre portail. Ils sont exclusivement destinés à être traités par les seuls employés de Howitreat qui doivent y avoir accès dans le cadre de l’exercice de leur fonction, ainsi qu’à ses sous-traitants éventuels pour des raisons exclusivement techniques et logistiques, et à ses partenaires notamment [le cas échéant, insérer le nom du partenaire et la finalité recherchée]. Les renseignements sont stockés sur nos serveurs, situés au Canada, et des mesures de sécurité physiques, organisationnelles, contractuelles et technologiques dans le but de les protéger ont été mises en place. Nous utiliserons, divulguerons ou conserverons ces enregistrements uniquement le temps nécessaire à la réalisation des objectifs poursuivis et dans la mesure permise ou requise par la loi. Vous disposez d’un droit d’accès et de rectification à l’égard de vos renseignements personnels et vous pouvez retirer votre consentement à tout moment. Pour toutes les questions que vous pourriez avoir, vous pouvez contacter notre Responsable à la protection des renseignements personnels aux coordonnées indiquées dans notre politique de confidentialité. Pour en savoir plus, cliquez ici: Politique de confidentialité

CAPTCHA

Connection

Disclaimer

We do not provide medical or professional advice.

Howitreat (the “Site” or “We”) provides the public and healthcare professionals with information about various types of cancers, their origins, available treatments, and helps optimize the internal logistics for healthcare professionals. It is designed to serve informational purposes and reflects my approach to practice. The Site should not be used as a replacement for a healthcare professional’s professional opinion, and should only be used to supplement standard medical practices. While we strive to provide accurate and up-to-date information, we cannot guarantee its completeness or timeliness. The Site may contain links to external websites or resources that are not controlled or maintained by us. We do not endorse or assume any responsibility for the content, accuracy, or availability of these external sites. The information provided through the Site is not a substitute for medical advice, and you should not rely on it for medical diagnosis, assessment, or treatment. We do not endorse or recommend any specific products or treatments mentioned on the Site. Your reliance on any information provided by us or available on the Site is at your own risk.

Always consult with your physician (or another qualified healthcare professional) for any questions or concerns regarding your personal health, medical conditions, medications, and before initiating or discontinuing any treatment, drug, or medication. Do not disregard, avoid, or delay seeking medical advice from your physician (or other qualified healthcare professional) based on any information you may have received or obtained through the Site.

Healthcare professionals or public must not, under any circumstances, provide or publish any personal information (including but not limited to the name) of any individuals on the Site.

Each physician (or another qualified healthcare professional) is responsible for his professional services and compliance with the requirements applicable to his profession and license. We will not be liable for any professional advice or healthcare services you obtain from a physician (or another qualified healthcare professional) through his use of the Site.

We disclaim all responsibility if a physician (or another qualified healthcare professional) shares a patient support program with third parties who are not healthcare professionals.